Introduction
Numerous new and novel antimicrobial agents have been introduced into infectious disease practice in the last decade to address emerging resistances among Gram-positive cocci. [1] [2] [3] Resistances to oxazolidinones, 2,3 streptogramin combinations 1 and various glycopeptides 2 require expanded development of agents with alternative targets or modes of action. Peptide deformylase, a required enzyme for prokaryote protein synthesis, has been suggested 4,5 as a potential target for inhibitors such as the potent hydroxamic acid derivatives. 6 The concept has been validated 7, 8 and several candidate agents have been screened. 7, 8 During initial development, resistance mechanisms were also described among multiple Gram-positive organisms including Staphylococcus aureus. [9] [10] [11] [12] In this investigation, NVP PDF-713, a new peptide deformylase inhibitor from a novel series of compounds, 13 was tested-using reference susceptibility test methods-14,15 against a collection of recent clinical isolates having documented resistances to linezolid or quinupristin/dalfopristin.
Materials and methods

Bacterial strains
A total of 45 organisms, originally isolated at resistance surveillance sites in the USA, Canada, Brazil and Europe, were selected from the stock culture collection (2001-2002) of JMI Laboratories (North Liberty, IA, USA). These organisms included Enterococcus faecalis (linezolid-resistant, three strains; quinupristin/dalfopristin resistance was intrinsic), Enterococcus faecium (linezolid-resistant, 10 strains; quinupristin/dalfopristin-resistant, six strains), S. aureus (linezolidresistant, five strains; quinupristin/dalfopristin-resistant, 10 strains), coagulase-negative staphylococci (linezolid-resistant, one strain; quinupristin/dalfopristin-resistant, nine strains) and Streptococcus oralis (linezolid-resistant, one strain). Definitions of resistance were those published by the NCCLS. 14,15 
Susceptibility testing
All susceptibility tests were performed using NCCLS M7-A6 methods 14 with 2%-5% lysed horse blood supplement for the fastidious streptococci. Cation-adjusted Mueller-Hinton broth was used for all other tested species. The mechanisms of resistance for all linezolid-resistant strains (MICs ≥ 8 mg/L) were confirmed by gene sequencing of the ribosomal target 3 and the detection of a G2576U mutation. The MICs of quinupristin/dalfopristin for quinupristin/dalfopristin-resistant strains were phenotypically confirmed by disc diffusion and Etest (AB Biodisk, Solna, Sweden) to have an MIC at ≥4 mg/L. PCR tests for vatD and vatE were negative. 1 Quality control (QC) of the NVP PDF-713 MIC results was performed using acceptable MIC ranges reported by Anderegg et al. 16 for QC strains S. aureus ATCC 29213, Streptococcus pneumoniae ATCC 49619 and E. faecalis ATCC 29212. All QC results for NVP PDF-713 16 and comparison agents used to categorize resistant isolates (linezolid, quinupristin/dalfopristin, vancomycin) were within NCCLS 15 published limits. Trays were manufactured by TREK Diagnostics (Cleveland, OH, USA) to specified NCCLS standards. 14 The proposed or tentative susceptible breakpoint for NVP PDF-713 to be applied by clinical trial laboratories was ≤8 mg/L based on pharmacokinetic/pharmacodynamic characteristics of this compound and similar peptide deformylase inhibitors. 17 Table 1 lists the results for all linezolid-or quinupristin/dalfopristinresistant enterococci. Among the 13 linezolid-resistant strains, three were E. faecalis and 10 were E. faecium. Also, 10 enterococci were resistant to vancomycin, and all E. faecalis strains had the characteristic intrinsic streptogramin resistance (MICs 8 mg/L). The MICs of NVP PDF-713 for these enterococci were in the range 0.5-4 mg/L (MIC 90 4 mg/L). The six quinupristin/dalfopristin-resistant E. faecium isolates were susceptible to vancomycin (MICs 1-4 mg/L) and also inhibited by 1 or 2 mg/L of NVP PDF-713.
Results and discussion
Similarly in Table 2 , NVP PDF-713 was highly active against linezolid-resistant S. aureus (MICs 0.25-0.5 mg/L), Staphylococcus epidermidis (MIC 2 mg/L) and the viridans group streptococcus isolate (MIC 0.5 mg/L), i.e. seven strains. Quinupristin/dalfopristin and vancomycin were also active against these oxazolidinone-resistant organisms. The quinupristin/dalfopristin-resistant staphylococci (19 strains) were susceptible to NVP PDF-713 (MIC range 0.12-2 mg/L), linezolid (MICs 1 or 2 mg/L) and vancomycin (MICs 1 or 2 mg/L).
These results indicate that NVP PDF-713, among the new candidate peptide deformylase inhibitors, 13 demonstrates excellent activity (all MICs ≤ 4 mg/L) against emerging Gram-positive clinical isolates that have become resistant to oxazolidinones (linezolid and 
AZD-2563) or streptogramin combinations. 1, 3 Since numerous members of this new peptide deformylase inhibitor class 4-7 may be advanced into clinical trials, close surveillance should be initiated for 'inhibitor-resistant' isolates, as predicted by early molecular studies. [9] [10] [11] [12] Continued development of agents in this class seems prudent and further synthetic modifications could enhance potency and other microbiological features, particularly against some Gram-negative species. 
